Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics)
  4. Volume 21, Issue 2
  5. Article
Volume 21, Issue 2
  • ISSN: 1875-6921
  • E-ISSN:

Abstract

Introduction

Metformin is a key treatment for type 2 diabetes, often linked to oxidative stress and genetic factors like GSTM1 and GSTT1 variations.

Methods

We studied 150 subjects, examining how their deletion polymorphisms in these genes correlate with Met treatment response. Those with GSTM1/T1 deletions (-/-) had a higher T2DM risk (2.71-fold, =0.005).

Results

Met responders with GSTM1(16bp) deletions had lower glucose levels compared to non-responders (<0.0001), and similar trends were observed with GSTT1(54bp) deletions. Responders with both deletions also managed lipids better (=0.0256; =0.0151). Non-responders with GSTM1/T1 null genotypes had better HDL management (=0.007).

Conclusion

These findings suggested that GSTM1 deletion could predict T2DM susceptibility and Met response.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cppm/10.2174/0118756921327075240909113640
2024-08-01
2024-11-26

  • From This Site

    /content/journals/cppm/10.2174/0118756921327075240909113640
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. International Diabetes Federation IDF Diabetes Atlas.10th edBrussels, BelgiumInternational Diabetes Federation2021
     [Google Scholar]
  2. World Health Organization.The top 10 causes of death. Available from: http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death(accessed on 27-8- 2024)
     [Google Scholar]
  3. ShamsadA. KushwahA.S. SinghR. BanerjeeM. Pharmaco-epi-genetic and patho-physiology of gestational diabetes mellitus (GDM): An overview.Health Sci. Rev. (Oxf.)2023710008610.1016/j.hsr.2023.100086
     [Google Scholar]
  4. World Health Organization World Health Organization. Diabetes.Available from: https://www.who.int/health-topics/diabetes#tab=tab_1(accessed on 27-8-2024)
  5. PradeepaR. MohanV. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation.Eur. J. Clin. Nutr.201771781682410.1038/ejcn.2017.40 28422124
     [Google Scholar]
  6. ShuklaA.K. ShamsadA. KushwahA.S. SinghS. UsmanK. BanerjeeM. CD36 gene variant rs1761667(G/A) as a biomarker in obese type 2 diabetes mellitus cases.Egypt. J. Med. Hum. Genet.2024251910.1186/s43042‑024‑00478‑6
     [Google Scholar]
  7. ShuklaA.K. AwasthiK. UsmanK. BanerjeeM. Role of renin-angiotensin system/angiotensin converting enzyme-2 mechanism and enhanced COVID-19 susceptibility in type 2 diabetes mellitus.World J. Diabetes202415460662210.4239/wjd.v15.i4.606 38680697
     [Google Scholar]
  8. ManninoG.C. SestiG. Individualized therapy for type 2 diabetes: Clinical implications of pharmacogenetic data.Mol. Diagn. Ther.201216528530210.1007/s40291‑012‑0002‑7 23018631
     [Google Scholar]
  9. Standards of Medical Care in Diabetes—2019 Abridged for Primary Care Providers.Clin. Diabetes2019371113410.2337/cd18‑0105 30705493
     [Google Scholar]
  10. Gonzalez-LopezC. WojeckB.S. Role of metformin in the management of type 2 diabetes: Recent advances.Pol Arch Intern Med202313361651110.20452/pamw.16511
     [Google Scholar]
  11. SinghS. UsmanK. BanerjeeM. Pharmacogenetic studies update in type 2 diabetes mellitus.World J. Diabetes201671530231510.4239/wjd.v7.i15.302 27555891
     [Google Scholar]
  12. JacobsC. PearceB. Du PlessisM. HoosainN. BenjeddouM. Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa.Genet. Mol. Biol.201437235035910.1590/S1415‑47572014005000002 25071399
     [Google Scholar]
  13. ZazuliZ. DuinN.J.C.B. JansenK. VijverbergS.J.H. Maitland-van der ZeeA.H. MasereeuwR. The impact of genetic polymorphisms in organic cation transporters on renal drug disposition.Int. J. Mol. Sci.20202118662710.3390/ijms21186627 32927790
     [Google Scholar]
  14. DuningK. WennmannD.O. BokemeyerA. Common exonic missense variants in the C2 domain of the human KIBRA protein modify lipid binding and cognitive performance.Transl. Psychiatry201336e27210.1038/tp.2013.49 23778582
     [Google Scholar]
  15. FeinbergH. RowntreeT.J.W. TanS.L.W. DrickamerK. WeisW.I. TaylorM.E. Common polymorphisms in human langerin change specificity for glycan ligands.J. Biol. Chem.201328852367623677110.1074/jbc.M113.528000 24217250
     [Google Scholar]
  16. HaraksinghR.R. SnyderM.P. Impacts of variation in the human genome on gene regulation.J. Mol. Biol.2013425213970397710.1016/j.jmb.2013.07.015 23871684
     [Google Scholar]
  17. PetrosinoM. NovakL. PasquoA. Analysis and interpretation of the impact of missense variants in cancer.Int. J. Mol. Sci.20212211541610.3390/ijms22115416 34063805
     [Google Scholar]
  18. XiaoD. GuoY. LiX. The impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms on metformin therapeutic efficacy in Chinese type 2 diabetes patients.Int. J. Endocrinol.201620161710.1155/2016/4350712 26977146
     [Google Scholar]
  19. HouW. ZhangD. LuW. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.Mol. Diagn. Ther.2015191253310.1007/s40291‑014‑0126‑z 25573751
     [Google Scholar]
  20. AbateN. ChandaliaM. Ethnicity and type 2 diabetes.J. Diabetes Complications200115632032710.1016/S1056‑8727(01)00161‑1 11711326
     [Google Scholar]
  21. MohanV. SandeepS. DeepaR. ShahB. VargheseC. Epidemiology of type 2 diabetes: Indian scenario.Indian J. Med. Res.20071253217230 17496352
     [Google Scholar]
  22. Akkuşİ. KalakS. VuralH. Leukocyte lipid peroxidation, superoxide dismutase, glutathione peroxidase and serum and leukocyte vitamin C levels of patients with type II diabetes mellitus.Clin. Chim. Acta1996244222122710.1016/0009‑8981(96)83566‑2 8714439
     [Google Scholar]
  23. TaysiS. PolatF. GulM. SariR. BakanE. Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis.Rheumatol. Int.200221520020410.1007/s00296‑001‑0163‑x 11958437
     [Google Scholar]
  24. YagiK. Increased serum lipid peroxides initiate atherogenesis.BioEssays198412586010.1002/bies.950010205
     [Google Scholar]
  25. GriesmacherA. KindhauserM. AndertS.E. Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus.Am. J. Med.199598546947510.1016/S0002‑9343(99)80347‑7 7733126
     [Google Scholar]
  26. GirónM.D. SaltoR. GonzálezY. Modulation of hepatic and intestinal Glutathione S-transferases and other antioxidant enzymes by dietary lipids in streptozotocin diabetic rats.Chemosphere199938133003301310.1016/S0045‑6535(98)00502‑5 10230044
     [Google Scholar]
  27. OparaE.C. Oxidative stress, micronutrients, diabetes mellitus and its complications.J. R. Soc. Promot. Health20021221283410.1177/146642400212200112 11989140
     [Google Scholar]
  28. FridlyandL. PhilipsonL.H. Oxidative reactive species in cell injury: Mechanisms in diabetes mellitus and therapeutic approaches.Ann. N. Y. Acad. Sci.20061066113615110.1196/annals.1363.019 16533924
     [Google Scholar]
  29. YoshidaK. HirokawaJ. TagamiS. KawakamiY. UrataY. KondoT. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: Regulation of glutathione synthesis and efflux.Diabetologia199538220121010.1007/BF00400095 7713315
     [Google Scholar]
  30. KimS.K. NovakR.F. The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression.Pharmacol. Ther.200711318812010.1016/j.pharmthera.2006.07.004 17097148
     [Google Scholar]
  31. HoriM. OnikiK. UedaK. Combined glutathione S-transferase T1 and M1 positive genotypes afford protection against type 2 diabetes in Japanese.Pharmacogenomics20078101307131410.2217/14622416.8.10.1307
     [Google Scholar]
  32. BidH.K. KonwarR. SaxenaM. ChaudhariP. AgrawalC.G. BanerjeeM. Association of glutathione S-transferase (GSTM1, T1 and P1) gene polymorphisms with type 2 diabetes mellitus in north Indian population.J. Postgrad. Med.201056317618110.4103/0022‑3859.68633 20739761
     [Google Scholar]
  33. ZakiM.A. MoghazyT.F. El-DeebM.M.K. MohamedA.H. MohamedN.A.A. Glutathione S-transferase M1, T1 and P1 gene polymorphisms and the risk of developing type 2 diabetes mellitus in Egyptian diabetic patients with and without diabetic vascular complications.Alex. J. Med.2015511738210.1016/j.ajme.2014.03.003
     [Google Scholar]
  34. Effect of metformin or gliclazide on lipid peroxidation and antioxidant levels in patients with diabetes mellitus.Turk. J. Med. Sci.2008386545548
     [Google Scholar]
  35. MohammedN.J. Evaluation the oxidative stress in patients with diabetes mellitus (Type I and type II) and study genetic level of glutathione-S-transferase mu 1.Evaluation2015512
     [Google Scholar]
  36. PolitiC. RoumeliotisS. TripepiG. SpotoB. Web 12. Politi C, Roumeliotis S, Tripepi G, Spoto B. Sample size calculation in genetic association studies: A practical approach.Life (Basel)202313123510.3390/life13010235 36676184
     [Google Scholar]
  37. BanerjeeM. BidH.K. KonwarR. AgrawalC.G. Association of IL-4 and IL-1RN (receptor antagonist) gene variants and the risk of type 2 diabetes mellitus: A study in the north Indian population.Indian J. Med. Sci.200862725926610.4103/0019‑5359.42021 18688110
     [Google Scholar]
  38. BanerjeeM. BidH.K. KonwarR. Vitamin D receptor (FokI, BsmI and TaqI) gene polymorphisms and type 2 diabetes mellitus: A North Indian study.Indian J. Med. Sci.200963518719410.4103/0019‑5359.53164 19584489
     [Google Scholar]
  39. HaH. KimK.H. Role of oxidative stress in the development of diabetic nephropathy.Kidney Int. Suppl.199551S18S21 7474682
     [Google Scholar]
  40. MillerS.A. DykesD.D. PoleskyH.F. A simple salting out procedure for extracting DNA from human nucleated cells.Nucleic Acids Res.1988163121510.1093/nar/16.3.1215 3344216
     [Google Scholar]
  41. KumarS. SwaroopS. SahuA. KantS. BanerjeeM. Association of MMP7 T > C gene variant (rs10502001) and expression in chronic obstructive pulmonary disease.DNA Cell Biol.202342954855310.1089/dna.2023.0150 37527206
     [Google Scholar]
  42. Abdel-RahmanS.Z. AnwarW.A. Abdel-AalW.E. MostafaH.M. AuW.W. GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer.Cancer Detect. Prev.199822212913810.1046/j.1525‑1500.1998.00934.x 9544433
     [Google Scholar]
  43. ShikataE. YamamotoR. TakaneH. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.J. Hum. Genet.200752211712210.1007/s10038‑006‑0087‑0 17111267
     [Google Scholar]
  44. ZhouK. DonnellyL.A. KimberC.H. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: A GoDARTS study.Diabetes20095861434143910.2337/db08‑0896 19336679
     [Google Scholar]
  45. Emami RiedmaierA. FiselP. NiesA.T. SchaeffelerE. SchwabM. Metformin and cancer: From the old medicine cabinet to pharmacological pitfalls and prospects.Trends Pharmacol. Sci.201334212613510.1016/j.tips.2012.11.005 23277337
     [Google Scholar]
  46. BeckerM.L. VisserL.E. van SchaikR.H.N. HofmanA. UitterlindenA.G. StrickerB.H.C. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus.Pharmacogenomics J.20099424224710.1038/tpj.2009.15 19381165
     [Google Scholar]
  47. TarasovaL. KalninaI. GeldnereK. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.Pharmacogenet. Genomics201222965966610.1097/FPC.0b013e3283561666 22735389
     [Google Scholar]
  48. SinghS. ShuklaA.K. UsmanK. BanerjeeM. Pharmacogenetic impact of SLC22A1 gene variant rs628031 (G/A) in newly diagnosed Indian type 2 diabetes patients undergoing metformin monotherapy.Pharmacogenet. Genomics2023333515810.1097/FPC.0000000000000493 36853844
     [Google Scholar]
  49. AL-Eitan LN. Almomani BA, Nassar AM, Elsaqa BZ, Saadeh NA. Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 polymorphisms on glycemic control and HbA1c levels.J. Pers. Med.2019911710.3390/jpm9010017 30934600
     [Google Scholar]
  50. AL-Eitan L. H Tarkhan A. Practical challenges and translational issues in pharmacogenomics and personalized medicine from 2010 onwards.Curr. Pharmacogenomics Person. Med.2016141717
     [Google Scholar]
  51. MarinJ.J. BrizO. MonteM.J. BlazquezA.G. MaciasR.I. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs.Curr. Cancer Drug Targets201212440243810.2174/156800912800190875 22229248
     [Google Scholar]
  52. TeitzT. WeiT. ValentineM.B. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.Nat. Med.20006552953510.1038/75007 10802708
     [Google Scholar]
  53. YanH. BrouhaB. LiuT. Proteolytic cleavage of Livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspase.J. Dermatol. Sci.200643318920010.1016/j.jdermsci.2006.05.007 16806840
     [Google Scholar]
  54. NegriF.V. BozzettiC. LagrastaC.A. PTEN status in advanced colorectal cancer treated with cetuximab.Br. J. Cancer2010102116216410.1038/sj.bjc.6605471 19953097
     [Google Scholar]
  55. TamiyaS. EtohK. SuzushimaH. TakatsukiK. MatsuokaM. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells.Blood199891103935394210.1182/blood.V91.10.3935 9573032
     [Google Scholar]
  56. BuczyńskaA. SidorkiewiczI. KrętowskiA.J. AdamskaA. Examining the clinical relevance of metformin as an antioxidant intervention.Front. Pharmacol.202415133079710.3389/fphar.2024.1330797 38362157
     [Google Scholar]
  57. ShokriF. GhaediH. Ghafouri FardS. Impact of ATM and SLC22A1 polymorphisms on therapeutic response to metformin in Iranian diabetic patients.Int. J. Mol. Cell. Med.20165117 27386433
     [Google Scholar]
  58. BaynesJ.W. ThorpeS.R. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm.Diabetes19994811910.2337/diabetes.48.1.1 9892215
     [Google Scholar]
  59. WangG. ZhangL. LiQ. Genetic polymorphisms of GSTT1, GSTM1, and NQO1 genes and diabetes mellitus risk in Chinese population.Biochem. Biophys. Res. Commun.2006341231031310.1016/j.bbrc.2005.12.195 16413497
     [Google Scholar]
  60. ShuY. BrownC. CastroR.A. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.Clin. Pharmacol. Ther.200883227328010.1038/sj.clpt.6100275 17609683
     [Google Scholar]
  61. SongI.S. ShinH.J. ShimE.J. Genetic variants of the organic cation transporter 2 influence the disposition of metformin.Clin. Pharmacol. Ther.200884555956210.1038/clpt.2008.61 18401339
     [Google Scholar]
  62. ChenY. LiS. BrownC. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.Pharmacogenet. Genomics200919749750410.1097/FPC.0b013e32832cc7e9 19483665
     [Google Scholar]
  63. YalinS. HatungilR. TamerL. Glutathione S‐transferase gene polymorphisms in Turkish patients with diabetes mellitus.Cell Biochem. Funct.2007255509513
     [Google Scholar]
  64. VerlaanM. te MorscheR.H.M. RoelofsH.M.J. Glutathione S‐transferase mu null genotype affords protection against alcohol induced chronic pancreatitis.Am. J. Med. Genet. A.2003120A1343910.1002/ajmg.a.20010 12794689
     [Google Scholar]
  65. NowierS.R. KashmiryN.K. RasoolH.A. MoradH. IsmailS. Association of type 2 diabetes mellitus and glutathione s transferase (GSTM1 and GSTT1) genetic polymorphism.Res J Medicine & Med Sci20094181188
     [Google Scholar]
  66. FujitaH. NaritaT. MeguroH. No association of glutathione S-transferase M1 gene polymorphism with diabetic nephropathy in Japanese type 2 diabetic patients.Ren. Fail.200022447948610.1081/JDI‑100100889 10901185
     [Google Scholar]
  67. DoneyA.S.F. LeeS. LeeseG.P. MorrisA.D. PalmerC.N.A. Increased cardiovascular morbidity and mortality in type 2 diabetes is associated with the glutathione S transferase theta-null genotype: A Go-DARTS study.Circulation2005111222927293410.1161/CIRCULATIONAHA.104.509224 15927971
     [Google Scholar]
/content/journals/cppm/10.2174/0118756921327075240909113640
Loading
Pharmacogenetics of Metformin Monotherapy: GSTM1/T1 Polymorphisms and T2DM Risk
Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) 21, 100 (2024); https://doi.org/10.2174/0118756921327075240909113640
/content/journals/cppm/10.2174/0118756921327075240909113640
/content/journals/cppm/10.2174/0118756921327075240909113640
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Glutathione S-transferase deletion polymorphism; metformin-antidiabetic therapy (Met-ADT); non-communicable diseases; pharmacogenetics; prognostic biomarker; type 2 diabetes mellitus (T2DM)
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test